Literature DB >> 25047018

The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever....

Lisa Bodei1, Mark Kidd, Vikas Prasad, Richard P Baum, Ignat Drozdov, Irvin M Modlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25047018     DOI： 10.1007/s00259-014-2836-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  44 in total

Review 1.  Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.

Authors:  Richard P Baum; Harshad R Kulkarni; Cecilia Carreras
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

2.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

3.  Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.

Authors:  C Kratochwil; E Mavriopoulou; D Rath; A Afshar-Oromieh; D Apostolopoulos; S Haufe; W Mier; U Haberkorn; F L Giesel
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-12-17       Impact factor: 2.346

Review 4.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.

Authors:  Jean Claude Reubi; Beatrice Waser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-18       Impact factor: 9.236

5.  Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.

Authors:  Damian Wild; Emanuel Christ; Martyn E Caplin; Tom R Kurzawinski; Flavio Forrer; Michael Brändle; Jochen Seufert; Wolfgang A Weber; Jamshed Bomanji; Aurel Perren; Peter J Ell; Jean Claude Reubi
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

6.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

Review 7.  Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.

Authors:  Anders Sundin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

8.  Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.

Authors:  Etienne Garin; Florence Le Jeune; Anne Devillers; Marc Cuggia; Anne-Sophie de Lajarte-Thirouard; Catherine Bouriel; Eveline Boucher; Jean-Luc Raoul
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

9.  Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.

Authors:  Olof Eriksson; Irina Velikyan; Ram K Selvaraju; Fouad Kandeel; Lars Johansson; Gunnar Antoni; Barbro Eriksson; Jens Sörensen; Olle Korsgren
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

10.  18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.

Authors:  Tina Binderup; Ulrich Knigge; Annika Loft; Birgitte Federspiel; Andreas Kjaer
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531
View more
  1 in total

1.  Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

Authors:  L Bodei; M Kidd; I M Modlin; V Prasad; S Severi; V Ambrosini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli; I Drozdov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.